Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis. A Randomized Trial Comparing Two Periodicities of Ultrasonographic Surveillance: 3-month vs 6-month
Patients: All consecutive patients with compensated HBV, HCV, alcohol or
hemochromatosis-related cirrhosis (without any previous clinical complication including
Randomization: factorial: ultrasonography (3-month versus 6-month); serum alfa-fetoprotein
assay (none versus 6-month).
End points: rate of small tumors (first main criteria); survival (second main criteria).
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label
Incidence of small hepatocellular carcinoma (HCC)
6 months versus 3 months
Jean-Claude Trinchet, Pr, MD, PhD
Assistance Publique - Hôpitaux de Paris
France: Ministry of Health